New Approved First-line Combining Therapy of NSCLC in 2020
In the past decades, lung cancer is considered one of the lethal cancers all across the world due to its evidenced greatest mortality and morbidity. Currently, the main clinical treatment methods for lung cancer involve surgery, chemotherapy, radiotherapy, anti-angiogenesis inhibitors and tyrosine k...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
EDP Sciences
2021-01-01
|
Series: | E3S Web of Conferences |
Online Access: | https://www.e3s-conferences.org/articles/e3sconf/pdf/2021/21/e3sconf_aeecs2021_03057.pdf |
id |
doaj-dfd9964cef6a4844a9aad26c50a6dc78 |
---|---|
record_format |
Article |
spelling |
doaj-dfd9964cef6a4844a9aad26c50a6dc782021-05-04T12:17:12ZengEDP SciencesE3S Web of Conferences2267-12422021-01-012450305710.1051/e3sconf/202124503057e3sconf_aeecs2021_03057New Approved First-line Combining Therapy of NSCLC in 2020Wang Nianwu0Wang Wei1Mao Wenli2Wang Kefeng3Zhang Haozhe4Ma Qiang5Kuerbantayi Nazuke6Wang YukunSchool of Medicine, Southern University of Science and TechnologyDepartment of Pharmaceutics and Pharmacy Administration, School of Pharmacy, Air Force Medical UniversitySchool of Medicine, Southern University of Science and TechnologySchool of Medicine, Southern University of Science and TechnologySchool of Medicine, Southern University of Science and TechnologySchool of Medicine, Southern University of Science and TechnologySchool of Medicine, Southern University of Science and TechnologyIn the past decades, lung cancer is considered one of the lethal cancers all across the world due to its evidenced greatest mortality and morbidity. Currently, the main clinical treatment methods for lung cancer involve surgery, chemotherapy, radiotherapy, anti-angiogenesis inhibitors and tyrosine kinase inhibitors. In the field of anticancer drugs, a variety of new anticancer drugs have been emerging in recent years. They include chemotherapy drugs with new delivery modes, targeted drugs for tyrosine kinase inhibitors, angiogenesis inhibitors, and immunotherapy drugs that have remained hot. But because cancer cells have complex escape mechanisms, the effectiveness of these single-drug treatments has been disappointing. In this case, a number of new combination therapies have emerged and achieved relatively good results. According to the 2020 third edition of the NCCN guidelines, four multi-therapy regiments (Erlotinib plus ramucirumab, Erlotinib plus bevacizumab, Carboplatin plus albumin-bound paclitaxel plus atezolizumab and Nivolumab plus ipilimumab) have passed clinical trials, adding first-line treatments. In this review, the research provided an overview of these four new approved combining treatment strategies in addition to predicting future drug development directions.https://www.e3s-conferences.org/articles/e3sconf/pdf/2021/21/e3sconf_aeecs2021_03057.pdf |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wang Nianwu Wang Wei Mao Wenli Wang Kefeng Zhang Haozhe Ma Qiang Kuerbantayi Nazuke Wang Yukun |
spellingShingle |
Wang Nianwu Wang Wei Mao Wenli Wang Kefeng Zhang Haozhe Ma Qiang Kuerbantayi Nazuke Wang Yukun New Approved First-line Combining Therapy of NSCLC in 2020 E3S Web of Conferences |
author_facet |
Wang Nianwu Wang Wei Mao Wenli Wang Kefeng Zhang Haozhe Ma Qiang Kuerbantayi Nazuke Wang Yukun |
author_sort |
Wang Nianwu |
title |
New Approved First-line Combining Therapy of NSCLC in 2020 |
title_short |
New Approved First-line Combining Therapy of NSCLC in 2020 |
title_full |
New Approved First-line Combining Therapy of NSCLC in 2020 |
title_fullStr |
New Approved First-line Combining Therapy of NSCLC in 2020 |
title_full_unstemmed |
New Approved First-line Combining Therapy of NSCLC in 2020 |
title_sort |
new approved first-line combining therapy of nsclc in 2020 |
publisher |
EDP Sciences |
series |
E3S Web of Conferences |
issn |
2267-1242 |
publishDate |
2021-01-01 |
description |
In the past decades, lung cancer is considered one of the lethal cancers all across the world due to its evidenced greatest mortality and morbidity. Currently, the main clinical treatment methods for lung cancer involve surgery, chemotherapy, radiotherapy, anti-angiogenesis inhibitors and tyrosine kinase inhibitors. In the field of anticancer drugs, a variety of new anticancer drugs have been emerging in recent years. They include chemotherapy drugs with new delivery modes, targeted drugs for tyrosine kinase inhibitors, angiogenesis inhibitors, and immunotherapy drugs that have remained hot. But because cancer cells have complex escape mechanisms, the effectiveness of these single-drug treatments has been disappointing. In this case, a number of new combination therapies have emerged and achieved relatively good results. According to the 2020 third edition of the NCCN guidelines, four multi-therapy regiments (Erlotinib plus ramucirumab, Erlotinib plus bevacizumab, Carboplatin plus albumin-bound paclitaxel plus atezolizumab and Nivolumab plus ipilimumab) have passed clinical trials, adding first-line treatments. In this review, the research provided an overview of these four new approved combining treatment strategies in addition to predicting future drug development directions. |
url |
https://www.e3s-conferences.org/articles/e3sconf/pdf/2021/21/e3sconf_aeecs2021_03057.pdf |
work_keys_str_mv |
AT wangnianwu newapprovedfirstlinecombiningtherapyofnsclcin2020 AT wangwei newapprovedfirstlinecombiningtherapyofnsclcin2020 AT maowenli newapprovedfirstlinecombiningtherapyofnsclcin2020 AT wangkefeng newapprovedfirstlinecombiningtherapyofnsclcin2020 AT zhanghaozhe newapprovedfirstlinecombiningtherapyofnsclcin2020 AT maqiang newapprovedfirstlinecombiningtherapyofnsclcin2020 AT kuerbantayinazuke newapprovedfirstlinecombiningtherapyofnsclcin2020 AT wangyukun newapprovedfirstlinecombiningtherapyofnsclcin2020 |
_version_ |
1721479350313811968 |